Removab

RSS

Withdrawn

This medicine's authorisation has been withdrawn

catumaxomab
MedicineHumanWithdrawn

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 2 June 2017, the European Commission withdrew the marketing authorisation for Removab (catumaxomab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Neovii Biotech GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Removab was granted marketing authorisation in the EU on 20 April 2009 for treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2013. The product had not been marketed in the EU since 2014. 

The European Public Assessment Report (EPAR) for Removab is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (619.17 KB - PDF)

Skatīt

español (ES) (487.88 KB - PDF)

Skatīt

čeština (CS) (601.56 KB - PDF)

Skatīt

dansk (DA) (487.88 KB - PDF)

Skatīt

Deutsch (DE) (489.31 KB - PDF)

Skatīt

eesti (ET) (499.17 KB - PDF)

Skatīt

ελληνικά (EL) (632.41 KB - PDF)

Skatīt

français (FR) (488.88 KB - PDF)

Skatīt

italiano (IT) (488.25 KB - PDF)

Skatīt

latviešu (LV) (602.02 KB - PDF)

Skatīt

lietuvių (LT) (570.59 KB - PDF)

Skatīt

magyar (HU) (593.2 KB - PDF)

Skatīt

Malti (MT) (617.05 KB - PDF)

Skatīt

Nederlands (NL) (510.15 KB - PDF)

Skatīt

polski (PL) (606.08 KB - PDF)

Skatīt

português (PT) (487.9 KB - PDF)

Skatīt

română (RO) (569.84 KB - PDF)

Skatīt

slovenčina (SK) (598.37 KB - PDF)

Skatīt

slovenščina (SL) (586.62 KB - PDF)

Skatīt

suomi (FI) (487.89 KB - PDF)

Skatīt

svenska (SV) (489.48 KB - PDF)

Skatīt

Product information

български (BG) (2.42 MB - PDF)

Skatīt

español (ES) (1.42 MB - PDF)

Skatīt

čeština (CS) (2.01 MB - PDF)

Skatīt

dansk (DA) (1.25 MB - PDF)

Skatīt

Deutsch (DE) (1.36 MB - PDF)

Skatīt

eesti (ET) (1.26 MB - PDF)

Skatīt

ελληνικά (EL) (2.49 MB - PDF)

Skatīt

français (FR) (1.39 MB - PDF)

Skatīt

hrvatski (HR) (1.35 MB - PDF)

Skatīt

italiano (IT) (1.29 MB - PDF)

Skatīt

latviešu (LV) (2.06 MB - PDF)

Skatīt

lietuvių (LT) (1.38 MB - PDF)

Skatīt

magyar (HU) (2.14 MB - PDF)

Skatīt

Malti (MT) (2.08 MB - PDF)

Skatīt

Nederlands (NL) (1.29 MB - PDF)

Skatīt

polski (PL) (2.21 MB - PDF)

Skatīt

português (PT) (1.28 MB - PDF)

Skatīt

română (RO) (1.54 MB - PDF)

Skatīt

slovenčina (SK) (2.05 MB - PDF)

Skatīt

slovenščina (SL) (2 MB - PDF)

Skatīt

suomi (FI) (1.29 MB - PDF)

Skatīt

svenska (SV) (1.27 MB - PDF)

Skatīt

Íslenska (IS) (1.27 MB - PDF)

Skatīt

norsk (NO) (1.76 MB - PDF)

Skatīt
Latest procedure affecting product information:IAIN/0020
02/06/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (520.46 KB - PDF)

Skatīt

español (ES) (456.72 KB - PDF)

Skatīt

čeština (CS) (509.49 KB - PDF)

Skatīt

dansk (DA) (456.81 KB - PDF)

Skatīt

Deutsch (DE) (456.81 KB - PDF)

Skatīt

eesti (ET) (457.58 KB - PDF)

Skatīt

ελληνικά (EL) (514.57 KB - PDF)

Skatīt

français (FR) (457.33 KB - PDF)

Skatīt

italiano (IT) (456.77 KB - PDF)

Skatīt

latviešu (LV) (513.5 KB - PDF)

Skatīt

lietuvių (LT) (496.02 KB - PDF)

Skatīt

magyar (HU) (504.19 KB - PDF)

Skatīt

Malti (MT) (511.71 KB - PDF)

Skatīt

Nederlands (NL) (456.72 KB - PDF)

Skatīt

polski (PL) (506.7 KB - PDF)

Skatīt

português (PT) (456.89 KB - PDF)

Skatīt

română (RO) (500.36 KB - PDF)

Skatīt

slovenčina (SK) (507.38 KB - PDF)

Skatīt

slovenščina (SL) (480.94 KB - PDF)

Skatīt

suomi (FI) (456.66 KB - PDF)

Skatīt

svenska (SV) (457.12 KB - PDF)

Skatīt

Product details

Name of medicine
Removab
Active substance
catumaxomab
International non-proprietary name (INN) or common name
catumaxomab
Therapeutic area (MeSH)
  • Ascites
  • Cancer
Anatomical therapeutic chemical (ATC) code
L01XC09

Pharmacotherapeutic group

Other antineoplastic agents

Therapeutic indication

Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.

Authorisation details

EMA product number
EMEA/H/C/000972
Marketing authorisation holder
Neovii Biotech GmbH

Am Haag 6-7
82166 Graefelfing
Germany

Marketing authorisation issued
20/04/2009
Withdrawal of marketing authorisation
02/06/2017
Revision
5

Assessment history

This page was last updated on

Share this page